Tradr 2X Long IBM Daily ETF

IBX

Valor de mercado US$ 43,5 mi

MELBOURNE, Australia--(BUSINESS WIRE)---- $IBX #FDA--Imagion Biosystems, Ltd. (ASX: IBX) announced it will resume MagSense® Nanoparticle manufacturing capabilities ahead of its Phase 1b/2 clinical trial and potential commercialization. The company has contracted nanoComposix, a nanoparticle Contract Development and Manufacturing Organization (CDMO). Under the signed agreement, Imagion will provide the proprietary nanoparticle synthesis equipment, software and procedures required for the CDMO to start manufac.

MELBOURNE, Australia--(BUSINESS WIRE)---- $IBX #FDA--IBX announced that it has secured firm commitments for AU$3.75M (US$2.59M) in new capital following the FDA's clearance of IND for a Phase 2 trial.

MELBOURNE, Australia--(BUSINESS WIRE)---- $IBX #FDA--Imagion's IND Application for HER2 MagSense® Imaging Agent Phase 2 Clinical Trial Has Cleared FDA Review. Company to proceed with clinical trial.